StockData
Starling Oncology, Inc. logo

Starling Oncology, Inc. (STLN) income statement

STLNNasdaqServices-Offices & Clinics of Doctors of MedicineFiscal year ends December 31Also trades as DFPH, STLNW
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/30
$3.20−0.20 (-5.88%)

Close on Nov 18, 2026Market cap $326.13MP/E –Yield –

Starling Oncology, Inc. income statement

Ratios

Latest available, balances at Sep 30, 2026

Profitability, TTM

Gross margin
–
Operating margin
-3.4%
Net margin
-5.7%
Return on equity, FY2025
999.2%

Financial strength

Current ratio
1.11
Debt to equity
-1.94
Debt to assets
38.6%
Cash to current liabilities
29.8%

Valuation

P/E ratio
–
Price to sales
0.53
Price to book
–
Dividend yield
–

See a number that looks wrong?